Format

Send to

Choose Destination
Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):291-7. doi: 10.1158/1055-9965.EPI-14-0636. Epub 2014 Oct 9.

Dietary intake of acrylamide and epithelial ovarian cancer risk in the european prospective investigation into cancer and nutrition (EPIC) cohort.

Author information

1
Unit of Nutrition, Environment, and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain.
2
Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom. Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, the Netherlands.
3
Dietary Exposure Assessment Group, International Agency for Research on Cancer, Lyon, France.
4
Inserm, Centre for research in Epidemiology and Population Health (CESP), U1018, Nutrition, Hormones, and Women's Health team, Villejuif, France. Univ Paris Sud, UMRS 1018, Villejuif, France. IGR, Villejuif, France.
5
Cancer Epidemiology Centre, Cancer Council of Victoria, Melbourne, Australia. Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Australia.
6
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
7
Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Nuthetal, Germany.
8
Danish Cancer Society Research Center, Copenhagen, Denmark.
9
Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark.
10
Public Health Directorate, Asturias, Spain.
11
Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria de Granada (Granada.ibs), Granada, Spain. Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública-CIBERESP), Madrid, Spain.
12
Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública-CIBERESP), Madrid, Spain. Public Health Division of Gipuzkoa-BIODONOSTIA, Basque Regional Health Department, Spain.
13
Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública-CIBERESP), Madrid, Spain. Department of Epidemiology, Murcia Regional Health Council, Murcia, Spain.
14
Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública-CIBERESP), Madrid, Spain. Navarre Public Health Institute, Pamplona, Spain.
15
University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.
16
MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom.
17
Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
18
Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.
19
Hellenic Health Foundation, Athens, Greece. Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece.
20
Hellenic Health Foundation, Athens, Greece. Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece. Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
21
Hellenic Health Foundation, Athens, Greece. Department of Hygiene, Epidemiology, and Medical Statistics, University of Athens Medical School, Goudi, Athens, Greece.
22
Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute - ISPO, Florence, Italy.
23
Epidemiology and Prevention Unit, Fondazione IRCSS Istituto Nazionale dei Tumori, Milano, Italy.
24
Cancer Registry and Histopathology Unit, "Civic - M.P. Arezzo" Hospital, ASP Ragusa, Italy.
25
Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom. Human Genetics Foundation, Torino, Italy.
26
Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.
27
Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom. National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, the Netherlands. Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
28
Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, the Netherlands.
29
Department of Clinical Sciences, Nutrition Epidemiology, Lund University, Malmö, Sweden.
30
Department of Clinical Sciences, Nutrition Epidemiology, Lund University, Malmö, Sweden. Umeå University, Department of Perioperative and Surgical Sciences, Sweden.
31
Department of Clinical Sciences, Obstetrics and Gynecology and Department of Public Health and Clinical Medicine, Nutritional Research, Umeå University, Umeå, Sweden.
32
Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
33
Department of Community Medicine, Faculty of Health Sciences, UiT The Artic University of Norway, Tromsø, Norway.
34
Department of Community Medicine, Faculty of Health Sciences, UiT The Artic University of Norway, Tromsø, Norway. Cancer Registry of Norway, Oslo, Norway. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Department of Genetic Epidemiology, Folkhälsan Research Center, Helsinki, Finland.
35
Unit of Nutrition, Environment, and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain. eduell@iconcologia.net.

Abstract

Acrylamide, classified in 1994 by the International Agency for Research on Cancer (IARC) as "probably carcinogenic" to humans, was discovered in 2002 in some heat-treated, carbohydrate-rich foods. The association between dietary acrylamide intake and epithelial ovarian cancer risk (EOC) has been previously studied in one case-control and three prospective cohort studies which obtained inconsistent results and could not further examine histologic subtypes other than serous EOC. The present study was carried out in the European Prospective Investigation into Cancer and Nutrition (EPIC) subcohort of women (n = 325,006). Multivariate Cox proportional hazards models were used to assess the association between questionnaire-based acrylamide intake and EOC risk. Acrylamide was energy-adjusted using the residual method and was evaluated both as a continuous variable (per 10 μg/d) and in quintiles; when subgroups by histologic EOC subtypes were analyzed, acrylamide intake was evaluated in quartiles. During a mean follow-up of 11 years, 1,191 incident EOC cases were diagnosed. At baseline, the median acrylamide intake in EPIC was 21.3 μg/d. No associations and no evidence for a dose-response were observed between energy-adjusted acrylamide intake and EOC risk (HR10μg/d,1.02; 95% CI, 0.96-1.09; HRQ5vsQ1, 0.97; 95% CI, 0.76-1.23). No differences were seen when invasive EOC subtypes (582 serous, 118 endometrioid, and 79 mucinous tumors) were analyzed separately. This study did not provide evidence that acrylamide intake, based on food intake questionnaires, was associated with risk for EOC in EPIC. Additional studies with more reliable estimates of exposure based on biomarkers may be needed.

PMID:
25300475
PMCID:
PMC4295892
DOI:
10.1158/1055-9965.EPI-14-0636
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center